JEMPERLI
PeakBLAINJECTIONINJECTABLEPriority Review
Approved
Aug 2021
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
JEMPERLI by GSK is pd-1 ligands, pd-l1 and pd-l2, to the pd-1 receptor found on t cells inhibits t-cell proliferation and cytokine production. Approved for recurrent endometrial cancer (ec), advanced ec, determined by an fda-approved test and 5 more indications. First approved in 2021.
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JEMPERLI (dostarlimab-gxly) is a humanized monoclonal antibody that blocks PD-1 receptor signaling to release anti-tumor immune responses. It is approved for endometrial cancer with mismatch repair deficiency (dMMR), a biomarker-defined indication with high clinical and commercial relevance. The drug works by inhibiting the PD-1 pathway-mediated suppression of T-cell proliferation and cytokine production.
$2MPart D
PeakEarly-stage peak commercial phase with modest Part D spending signals emerging adoption in a niche biomarker-defined population; medical affairs and field teams remain critical to physician education.
Mechanism of Action
PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors, and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.…
Indications (7)
Worked on JEMPERLI at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.